US Patent Issued to JANUX THERAPEUTICS on Sept. 1 for "Tumor activated antibodies targeting TROP2 and uses thereof" (California Inventors)

ALEXANDRIA, Va., Sept. 1 -- United States Patent no. 12,723,099, issued on Sept. 1, was assigned to JANUX THERAPEUTICS INC. (San Diego).

"Tumor activated antibodies targeting TROP2 and uses thereof" was invented by David Campbell (San Diego) and Thomas R. Diraimondo (San Diego).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are isolated polypeptides or polypeptide complexes that comprise a tumor-associated calcium signal transducer 2 (TROP2) binding domain that has been optimized for binding and kinetic properties. In some embodiments, the isolated polypeptides or polypeptide complexes further comprise a CD3 binding domain."

The patent was filed on May 8, 2023, under Application No. 18/314,0...